Apellis Pharmaceuticals Inc (APLS) Technical Analysis
$40.90▲0.07%
Market is closed - opens 7 PM, 20 Apr 2026
Insights
- Apellis Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Apellis Pharmaceuticals stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Apellis Pharmaceuticals stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Apellis Pharmaceuticals stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 87.58 | Sell |
Stochastic | 99.79, 99.85 | Sell |
Ultimate Oscillator | 84.09 | Sell |
Stochastic Relative Strength Index | 99.85, 99.84 | Neutral |
Moving Average Convergence Divergence | 5.43, 5.0 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 40.78 | Buy |
20 | 32.51 | Buy |
50 | 25.52 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 39.09 | Buy |
20 | 34.7 | Buy |
50 | 28.47 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 40.76 | Neutral |
20 | 38.34 | Buy |
50 | 34.17 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 43.12 | Buy |
20 | 41.81 | Buy |
50 | 33.83 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 42.22 | Sell |
20 | 44.78 | Buy |
50 | 38.03 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 41.01 |
Resistance L2 | 40.95 |
Resistance L1 | 40.91 |
Pivot Point | 40.85 |
Support L1 | 40.82 |
Support L2 | 40.76 |
Support L3 | 40.72 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.